A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL, ACTIVE-CONTROL STUDY OF THE EFFECTS OF SPARSENTAN, A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, ON RENAL OUTCOMES IN PATIENTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
Clinical Trial Grant
Administered By
Pediatrics, Nephrology
Awarded By
Retrophin, Inc.
Start Date
June 16, 2020
End Date
June 14, 2023
Administered By
Pediatrics, Nephrology
Awarded By
Retrophin, Inc.
Start Date
June 16, 2020
End Date
June 14, 2023